Document is current
Any future updates will be listed below
-
Authors
Sandén, Carl https://orcid.org/0000-0002-8931-9565
Landberg, Niklas https://orcid.org/0000-0001-6752-6507
Peña-Martínez, Pablo https://orcid.org/0000-0002-0789-6431
Thorsson, Hanna https://orcid.org/0000-0001-5393-2942
Daga, Shruti
Puente-Moncada, Noelia
Rodriguez-Zabala, Maria
von Palffy, Sofia
Rissler, Marianne
Lazarevic, Vladimir https://orcid.org/0000-0002-1782-4423
Juliusson, Gunnar
Ohlin, Mats https://orcid.org/0000-0002-5105-1938
Hyrenius-Wittsten, Axel
Orsmark-Pietras, Christina https://orcid.org/0000-0002-6533-0305
Lilljebjörn, Henrik https://orcid.org/0000-0001-8703-1173
Ågerstam, Helena
Fioretos, Thoas https://orcid.org/0000-0002-3235-6154
- License Information
-
More Information
Article History
Received: 19 January 2024
Accepted: 26 August 2025
First Online: 3 October 2025
Competing interests
: C.S. and N.L. are cofounders with equity in Lead Biologics International. T.F. is a cofounder and board member with equity in Lead Biologics International. C.S., N.L. and T.F. are inventors on patent applications on therapeutic targeting of SLAMF6, including but not limited to the TNC-1 antibody (including patent families WO2021111005 and WO2024240896 owned by Lead Biologics International). The other authors declare no competing interests.
